One of the CEPHALOSPORINS that has a broad spectrum of activity against both gram-positive and gram-negative microorganisms.
Semisynthetic broad-spectrum cephalosporin.
Semisynthetic penicillin-type antibiotic.
A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
A cephalosporin antibiotic that is administered intravenously or intramuscularly. It is active against most common gram-positive and gram-negative microorganisms, is a potent inhibitor of Enterobacteriaceae, and is highly resistant to hydrolysis by beta-lactamases. The drug has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.
A pyridinium-substituted semisynthetic, broad-spectrum antibacterial used especially for Pseudomonas infections in debilitated patients.
A neuropsychological disorder related to alterations in DOPAMINE metabolism and neurotransmission involving frontal-subcortical neuronal circuits. Both multiple motor and one or more vocal tics need to be present with TICS occurring many times a day, nearly daily, over a period of more than one year. The onset is before age 18 and the disturbance is not due to direct physiological effects of a substance or a another medical condition. The disturbance causes marked distress or significant impairment in social, occupational, or other important areas of functioning. (From DSM-IV, 1994; Neurol Clin 1997 May;15(2):357-79)
Historical term for a chronic, but fluctuating, disorder beginning in early life and characterized by recurrent and multiple somatic complaints not apparently due to physical illness. This diagnosis is not used in contemporary practice.
The behavior of performing an act persistently and repetitively without it leading to reward or pleasure. The act is usually a small, circumscribed behavior, almost ritualistic, yet not pathologically disturbing. Examples of compulsive behavior include twirling of hair, checking something constantly, not wanting pennies in change, straightening tilted pictures, etc.
A country in western Europe bordered by the Atlantic Ocean, the English Channel, the Mediterranean Sea, and the countries of Belgium, Germany, Italy, Spain, Switzerland, the principalities of Andorra and Monaco, and by the duchy of Luxembourg. Its capital is Paris.
An anxiety disorder characterized by recurrent, persistent obsessions or compulsions. Obsessions are the intrusive ideas, thoughts, or images that are experienced as senseless or repugnant. Compulsions are repetitive and seemingly purposeful behavior which the individual generally recognizes as senseless and from which the individual does not derive pleasure although it may provide a release from tension.
"The History of Nursing is a field of study that examines the evolution and development of nursing as a profession, including its theories, practices, educators, institutions, and social context from ancient times to the present."
Disorders characterized by recurrent TICS that may interfere with speech and other activities. Tics are sudden, rapid, nonrhythmic, stereotyped motor movements or vocalizations which may be exacerbated by stress and are generally attenuated during absorbing activities. Tic disorders are distinguished from conditions which feature other types of abnormal movements that may accompany another another condition. (From DSM-IV, 1994)

Protection with antibody to tumor necrosis factor differs with similarly lethal Escherichia coli versus Staphylococcus aureus pneumonia in rats. (1/31)

BACKGROUND: Differing factors may alter the effects of antibody to tumor necrosis factor (TNF) in infection and sepsis. The authors tested whether bacteria type or treatment route alters antibody to TNF in a rat model of bacterial pneumonia. METHODS: Rats (n = 231) received similarly lethal doses of either intratracheal Escherichia coli or Staphylococcus aureus followed by treatment with either intratracheal or intraperitoneal antibody to TNF or control serum. Animals received antibiotics (cefotiam daily dose, 100 mg/kg) starting 4 h after inoculation and were studied for up to 96 h. RESULTS: Compared with S. aureus, E. coli increased serum TNF and interleukin-6 concentrations, lung lavage TNF concentrations, neutrophil counts, and alveolar-to-arterial oxygen gradients and decreased circulating neutrophils and lymphocytes (P > or = 0.05 for all). Compared with controls, with both bacteria, except for lung lavage TNF concentrations (which decreased with intratracheal but not with intraperitoneal antibody to TNF), treatment route did not alter the effects of antibody to TNF on any parameter (P = not significant for all). Antibody to TNF reduced mortality rates (relative risk of death +/- SEM) with both E. coli (-1.6 +/- 0.6; P = 0.006) and S. aureus (-0.5 +/- 0.04; P = 0.185), but these reductions were greater with E. coli than with S. aureus in a trend approaching statistical significance (P = 0.09). Compared with controls, similarly (P = not significant) with both bacteria, antibody to TNF decreased lung lavage and tissue bacteria concentrations (both P < 0.05) and serum TNF concentration (P < 0.09) and increased circulating neutrophils and lymphocytes (both P < or = 0.01). Compared with S. aureus, with E. coli antibody to TNF decreased alveolar-to-arterial oxygen gradients (P = 0.04) and increased serum interleukin-6 concentrations (P = 0.003). CONCLUSION: Antibody to TNF improved host defense and survival rates with both lethal E. coli and S. aureus pneumonia, but protection was greater with E. coli, where TNF concentrations were higher than with S. aureus. The efficacy of antiinflammatory agents in sepsis may be altered by bacteria type.  (+info)

Cl- -dependent upregulation of human organic anion transporters: different effects on transport kinetics between hOAT1 and hOAT3. (2/31)

Chloride ion has a stimulatory effect on the transport of organic anions across renal basolateral membranes. However, the exact mechanisms at molecular levels have been unclear as of yet. Human organic anion transporters hOAT1 and hOAT3 play important roles in renal basolateral membranes. In this study, the effects of Cl(-) on the activities of these transporters were evaluated by using HEK293 cells stably expressing hOAT1 or hOAT3 (HEK-hOAT1 or HEK-hOAT3). The uptake of p-[(14)C]aminohippurate by HEK-hOAT1 and [(3)H]estrone sulfate by HEK-hOAT3 was greater in the presence of Cl(-) than in the presence of SO(4)(2-) or gluconate. Additionally, the uptake of various compounds by HEK-hOAT1 and HEK-hOAT3 was significantly higher in the Cl(-)-containing medium than the gluconate-containing medium, suggesting that the influences of Cl(-) are not dependent on substrate and that Cl(-) directly stimulates the functions of hOAT1 and hOAT3. The substitution of gluconate with Cl(-) did not change the K(m) value for the uptake of p-[(14)C]aminohippurate by HEK-hOAT1 but caused an approximately threefold increase in the maximal uptake rate (V(max)) value. On the other hand, replacement of gluconate with Cl(-) decreased the K(m) value for the uptake of [(3)H]estrone sulfate and cefotiam by HEK-hOAT3 to about one-third, while it did not change the V(max) value. In summary, Cl(-) upregulates the activities of both hOAT1 and hOAT3, but its effects on transport kinetics differ between these transporters. It was suggested that Cl(-) participates in the trans-location process for hOAT1, and the substrate recognition process for hOAT3.  (+info)

Adaptive responses of renal organic anion transporter 3 (OAT3) during cholestasis. (3/31)

 (+info)

Multidrug-resistant Neisseria gonorrhoeae with reduced cefotaxime susceptibility is increasingly common in men who have sex with men, Amsterdam, the Netherlands. (4/31)

Antimicrobial resistance is an increasing problem in Neisseria gonorrhoeae (NG) treatment. Presently, third-generation parenteral cephalosporins, like ceftriaxone and cefotaxime, are the first option. Resistance to oral, but not to parenteral, third-generation cephalosporins has been reported previously. We analysed the microbial susceptibility (as minimum inhibitory concentration - MIC) of NG cultures obtained from high-risk visitors of the largest Dutch outpatient clinic for sexually transmitted infections (STI) in Amsterdam, the Netherlands. Among 1,596 visitors, we identified 102 patients with at least one NG isolate with reduced susceptibility to cefotaxime (0.125 microg/ml < MIC < or = 0.5 microg/ml). The percentage of NG isolates with reduced susceptibility to cefotaxime rose from 4.8% in 2006 to 12.1% in 2008 (chi2 17.5, p<0.001). With multivariate logistic regression, being a man who has sex with men (MSM) was significantly associated with reduced susceptibility to cefotaxime (p<0.001). Compared to susceptible NG isolates, those with decreased susceptiblity to cefotaxime were more often resistant also to penicillin (16.5% vs. 43.3%), tetracycline (21.5% vs. 68.9%) and ciprofloxacin (44.4% vs. 90.0%, all p<0.001). The increased prevalence of NG strains with reduced susceptibility to cefotaxime among MSM may herald resistance to third-generation parenteral cephalosporins. A considerable proportion of these strains show resistance to multiple antibiotics which could limit future NG treatment options.  (+info)

Molecular-weight-dependent, anionic-substrate-preferential transport of beta-lactam antibiotics via multidrug resistance-associated protein 4. (5/31)

 (+info)

Interaction of cefpirome and a cephalosporinase from Citrobacter freundii GN7391. (6/31)

The interaction of cefpirome and a cephalosporinase from Citrobacter freundii, including hydrolysis and inhibition, was studied in comparison with those of cefotiam, cefotaxime, and ceftazidime. Cefpirome was hydrolyzed by the enzyme more rapidly at Vmax than were cefotaxime and ceftazidime. However, the low affinity of the enzyme for cefpirome caused a reduction in the hydrolytic rate of cefpirome at a low drug concentration (0.1 microM). The high stability of cefpirome at a low concentration explains the high antimicrobial activity of the agent against cephalosporinase-producing bacteria.  (+info)

Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers. (7/31)

Markedly obese athletes like Japanese sumo wrestlers may frequently suffer various traumas which result in the prophylaxis or treatment of posttraumatic infection with antibiotics. However, appropriate dosage regimens in this group of patients have not been fully known for many antibiotics. Therefore, we studied the kinetic disposition of cefotiam, a parenteral, broad-spectrum cephalosporin with activity against gram-positive and -negative bacteria, after an intravenous dose (2 g) infused over 30 min into 15 sumo wrestler patients with an excess body weight (130 to 220% of ideal body weight) and 10 control patients with a normal weight (90 to 102% of ideal body weight). Mean (+/- standard deviation) clearance and steady-state volume of distribution were significantly greater in the sumo wrestler than in the control group (38.3 +/- 9.4 versus 23.5 +/- 6.0 liters/h, P less than 0.001, and 30.2 +/- 8.0 versus 17.9 +/- 6.1 liters, P less than 0.001). Mean elimination half-life was slightly but significantly longer in the sumo wrestler than in the control group (0.91 +/- 0.14 versus 0.74 +/- 0.20 h, P less than 0.05). However, mean residence time did not differ between the two groups (0.79 +/- 0.10 versus 0.75 +/- 0.14 h). The statistical differences in clearance and volume of distribution between the two groups disappeared when these kinetic parameters were corrected for body surface area, but not for total body weight or ideal body weight. The results suggest that the dosage calculation of cefotiam, a hydrophilic antibiotic, should be made on the basis of body surface area in morbidly obese athlete or sumo wrestler patients. However, whether this recommendation should extend to other nonathlete obese subjects remains to be determined.  (+info)

In vitro evaluation of E1040, a new cephalosporin with potent antipseudomonal activity. (8/31)

E1040 is a new parenteral cephalosporin with a broad antibacterial spectrum and potent antipseudomonal activity. The compound was four- to eightfold more active than ceftazidime and cefsulodin against Pseudomonas aeruginosa (MIC of E1040 for 90% of strains tested [MIC90], 3.13 micrograms/ml). E1040 also showed a potent activity against other glucose-nonfermentative rods, including Acinetobacter species. The activities of E1040 against most species of the family Enterobacteriaceae were roughly comparable to the activities of ceftazidime and cefmenoxime and exceeded that of cefotiam. Against Citrobacter freundii (MIC90, 0.78 micrograms/ml), Enterobacter cloacae (MIC90, 3.13 micrograms/ml), and Enterobacter aerogenes (MIC90, 0.2 micrograms/ml), E1040 was 16- to 256-fold more active than ceftazidime and cefmenoxime. The activities of E1040 against gram-positive cocci and anaerobes were comparable to those of ceftazidime, but the compound was less active than cefmenoxime. E1040 was at least as resistant as ceftazidime and cefmenoxime to hydrolysis by various beta-lactamases and showed high affinities for penicillin-binding protein 3 of both Escherichia coli and P. aeruginosa.  (+info)

Cefotiam is a type of antibiotic known as a cephalosporin, which is used to treat various bacterial infections. It works by interfering with the bacteria's ability to form a cell wall, leading to bacterial cell death. Cefotiam has a broad spectrum of activity and is effective against many gram-positive and gram-negative bacteria.

Here is the medical definition of 'Cefotiam':

Cefotiam is a semisynthetic, broad-spectrum, beta-lactam antibiotic belonging to the cephalosporin class. It has activity against both gram-positive and gram-negative bacteria, including many strains that are resistant to other antibiotics. Cefotiam inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bacterial cell death.

Cefotiam is available in various formulations, including intravenous (IV) and intramuscular (IM) injections, for the treatment of a wide range of infections, such as:

* Lower respiratory tract infections (e.g., pneumonia, bronchitis)
* Urinary tract infections (e.g., pyelonephritis, cystitis)
* Skin and soft tissue infections (e.g., cellulitis, wound infections)
* Bone and joint infections (e.g., osteomyelitis, septic arthritis)
* Intra-abdominal infections (e.g., peritonitis, appendicitis)
* Septicemia (bloodstream infections)

Cefotiam is generally well tolerated, but like other antibiotics, it can cause side effects, including gastrointestinal symptoms (e.g., nausea, vomiting, diarrhea), skin rashes, and allergic reactions. In rare cases, cefotiam may cause serious adverse effects, such as seizures, interstitial nephritis, or hemorrhagicystitis. It should be used with caution in patients with a history of allergy to beta-lactam antibiotics, impaired renal function, or a history of seizure disorders.

It is essential to complete the full course of treatment as prescribed by a healthcare professional, even if symptoms improve, to ensure that the infection is entirely eradicated and to reduce the risk of developing antibiotic resistance.

Cefotaxime is a third-generation cephalosporin antibiotic, which is used to treat a variety of bacterial infections. It works by inhibiting the synthesis of the bacterial cell wall. Cefotaxime has a broad spectrum of activity and is effective against many Gram-positive and Gram-negative bacteria, including some that are resistant to other antibiotics.

Cefotaxime is often used to treat serious infections such as pneumonia, meningitis, and sepsis. It may also be used to prevent infections during surgery or in people with weakened immune systems. The drug is administered intravenously or intramuscularly, and its dosage depends on the type and severity of the infection being treated.

Like all antibiotics, cefotaxime can cause side effects, including diarrhea, nausea, vomiting, and rash. In rare cases, it may cause serious allergic reactions or damage to the kidneys or liver. It is important to follow the prescribing physician's instructions carefully when taking this medication.

I'm sorry for any confusion, but "Sulbenicillin" is not a recognized or established term in medical science or pharmacology. It seems that there might be a spelling mistake or a mix-up with the names of antibiotics. If you meant "Subenicillin," it also doesn't exist in medical literature as a known drug.

If you have any other questions about medical definitions, please provide the correct term, and I will be happy to help.

Cefazolin is a type of antibiotic known as a cephalosporin, which is used to treat a variety of bacterial infections. It works by interfering with the bacteria's ability to form a cell wall, which is necessary for its survival. Without a functional cell wall, the bacteria are not able to grow and multiply, and are eventually destroyed by the body's immune system.

Cefazolin is commonly used to treat infections of the skin, bones, joints, heart, lungs, and urinary tract. It may also be used to prevent infection during surgery. Like all antibiotics, cefazolin is only effective against certain types of bacteria, so it is important to know the specific type of bacteria causing an infection before using this medication.

Cefazolin is usually given as an injection into a vein or muscle, and may be administered in a hospital setting or at home with proper training. The dosage and duration of treatment will depend on the severity and location of the infection, as well as the patient's overall health status.

As with any medication, cefazolin can cause side effects, including diarrhea, nausea, vomiting, headache, and rash. In rare cases, it may also cause serious side effects such as allergic reactions, kidney damage, or abnormal blood clotting. It is important to report any unusual symptoms to a healthcare provider promptly.

It is essential to complete the full course of treatment with cefazolin, even if symptoms improve, to ensure that the infection is fully treated and to reduce the risk of antibiotic resistance.

Cefmenoxime is a second-generation cephalosporin antibiotic, which is used to treat various bacterial infections. It works by inhibiting the synthesis of the bacterial cell wall. Cefmenoxime has a broad spectrum of activity against both Gram-positive and Gram-negative bacteria, including some strains that are resistant to other antibiotics.

Common indications for cefmenoxime include respiratory tract infections, urinary tract infections, skin and soft tissue infections, bone and joint infections, and intra-abdominal infections. It is also used as a prophylactic agent during surgery to reduce the risk of postoperative infections.

Cefmenoxime is usually administered intravenously or intramuscularly, and its dosage may vary depending on the type and severity of the infection, as well as the patient's age and renal function. Common side effects of cefmenoxime include gastrointestinal symptoms such as diarrhea, nausea, and vomiting, as well as allergic reactions such as rash, itching, and hives.

It is important to note that the use of antibiotics should be based on a careful assessment of the patient's condition and the susceptibility of the infecting organism. Overuse or misuse of antibiotics can lead to the development of antibiotic resistance, which can make subsequent infections more difficult to treat.

Cefsulodin is a type of antibiotic known as a cephalosporin, which is used to treat various bacterial infections. It works by interfering with the bacteria's ability to form a cell wall, which is necessary for its survival. By damaging the cell wall, Cefsulodin causes the bacterium to become unstable and eventually die.

Cefsulodin is a broad-spectrum antibiotic, which means it is effective against a wide range of bacteria. It is often used to treat infections caused by Gram-negative bacteria, such as Pseudomonas aeruginosa, which can be difficult to treat with other types of antibiotics.

Cefsulodin is usually given by injection into a vein (intravenously) or muscle (intramuscularly). It may also be given as a topical solution for skin infections. As with all antibiotics, Cefsulodin should only be used under the direction of a healthcare provider, and it is important to take the full course of treatment as prescribed, even if symptoms improve before the medication is finished.

Like other cephalosporins, Cefsulodin can cause side effects such as diarrhea, nausea, vomiting, and rash. In rare cases, it may also cause serious side effects such as an allergic reaction, kidney damage, or seizures. It is important to inform your healthcare provider of any medical conditions you have and any medications you are taking before starting treatment with Cefsulodin.

Tourette Syndrome (TS) is a neurological disorder characterized by the presence of multiple motor tics and at least one vocal (phonic) tic. These tics are sudden, repetitive, rapid, involuntary movements or sounds that occur for more than a year and are not due to substance use or other medical conditions. The symptoms typically start before the age of 18, with the average onset around 6-7 years old.

The severity, frequency, and types of tics can vary greatly among individuals with TS and may change over time. Common motor tics include eye blinking, facial grimacing, shoulder shrugging, and head or limb jerking. Vocal tics can range from simple sounds like throat clearing, coughing, or barking to more complex phrases or words.

In some cases, TS may be accompanied by co-occurring conditions such as attention deficit hyperactivity disorder (ADHD), obsessive-compulsive disorder (OCD), anxiety, and depression. These associated symptoms can sometimes have a greater impact on daily functioning than the tics themselves.

The exact cause of Tourette Syndrome remains unclear, but it is believed to involve genetic factors and abnormalities in certain brain regions involved in movement control and inhibition. There is currently no cure for TS, but various treatments, including behavioral therapy and medications, can help manage the symptoms and improve quality of life.

The term "hysteria" is an outdated and discredited concept in medicine, particularly in psychiatry and psychology. Originally, it was used to describe a condition characterized by dramatic, excessive emotional reactions and physical symptoms that couldn't be explained by a medical condition. These symptoms often included things like paralysis, blindness, or fits, which would sometimes be "hysterical" in nature - that is, they seemed to have no physical cause.

However, the concept of hysteria has been largely abandoned due to its lack of scientific basis and its use as a catch-all diagnosis for symptoms that doctors couldn't explain. Today, many of the symptoms once attributed to hysteria are now understood as manifestations of other medical or psychological conditions, such as conversion disorder, panic attacks, or malingering. It's important to note that using outdated and stigmatizing terms like "hysteria" can be harmful and misleading, so it's best to avoid them in favor of more precise and respectful language.

Compulsive behavior is a type of repetitive behavior that an individual feels driven to perform, despite its negative impact on their daily life and mental health. It is often driven by an overwhelming urge or anxiety, and the person may experience distress if they are unable to carry out the behavior. Compulsive behaviors can be associated with various psychiatric conditions, including obsessive-compulsive disorder (OCD), body dysmorphic disorder, eating disorders, and impulse control disorders.

Examples of compulsive behaviors include:

1. Excessive handwashing or cleaning
2. Repeatedly checking locks, light switches, or appliances
3. Ordering or arranging items in a specific way
4. Compulsive hoarding
5. Compulsive shopping or spending
6. Compulsive eating or purging behaviors (such as those seen in bulimia nervosa)
7. Compulsive sexual behavior (sex addiction)
8. Compulsive exercise
9. Compulsive hair pulling (trichotillomania)
10. Compulsive skin picking (excoriation disorder)

Treatment for compulsive behaviors typically involves a combination of medication, psychotherapy (such as cognitive-behavioral therapy), and lifestyle changes to help manage the underlying causes and reduce the urge to engage in the compulsive behavior.

I'm sorry for any confusion, but "France" is not a medical term or concept. France is the largest country in Western Europe and the third-largest in Europe after Russia and Ukraine. It has been a major player in world affairs for centuries, with a significant cultural and artistic influence. If you have any questions about medical terms or concepts, I would be happy to help answer those for you.

Obsessive-Compulsive Disorder (OCD) is a mental health disorder characterized by the presence of obsessions and compulsions. Obsessions are recurrent and persistent thoughts, urges, or images that are intrusive, unwanted, and often distressing. Compulsions are repetitive behaviors or mental acts that an individual feels driven to perform in response to an obsession or according to rigid rules, and which are aimed at preventing or reducing anxiety or distress, or preventing some dreaded event or situation. These obsessions and/or compulsions cause significant distress, take up a lot of time (an hour or more a day), and interfere with the individual's daily life, including social activities, relationships, and work or school performance. OCD is considered a type of anxiety disorder and can also co-occur with other mental health conditions.

A "History of Nursing" in a medical context generally refers to the documentation of a patient's past experiences with nursing care, including any previous hospitalizations, treatments, medications, and interactions with nursing staff. This information is used by nurses to assess a patient's current health status, identify potential risks or complications, and develop an individualized plan of care.

The history of nursing can include information about the patient's medical history, surgical history, family medical history, social history, and lifestyle factors that may impact their health. It is important for nurses to gather this information accurately and thoroughly, as it can help them provide safe and effective care, communicate with other healthcare providers, and promote positive health outcomes for their patients.

In addition to its clinical importance, the history of nursing also plays a critical role in nursing education and research, helping to inform best practices, advance nursing science, and shape the future of the profession.

Tic disorders are a group of conditions characterized by the presence of repetitive, involuntary movements or sounds, known as tics. These movements or sounds can vary in complexity and severity, and they may be worsened by stress or strong emotions.

There are several different types of tic disorders, including:

1. Tourette's disorder: This is a neurological condition characterized by the presence of both motor (movement-related) and vocal tics that have been present for at least one year. The tics may wax and wane in severity over time, but they do not disappear for more than three consecutive months.
2. Persistent (chronic) motor or vocal tic disorder: This type of tic disorder is characterized by the presence of either motor or vocal tics (but not both), which have been present for at least one year. The tics may wax and wane in severity over time, but they do not disappear for more than three consecutive months.
3. Provisional tic disorder: This type of tic disorder is characterized by the presence of motor or vocal tics (or both) that have been present for less than one year. The tics may wax and wane in severity over time, but they do not disappear for more than three consecutive months.
4. Tic disorder not otherwise specified: This category is used to describe tic disorders that do not meet the criteria for any of the other types of tic disorders.

Tic disorders are thought to be caused by a combination of genetic and environmental factors, and they often co-occur with other conditions such as attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD). Treatment for tic disorders may include behavioral therapy, medication, or a combination of both.

... is a parenteral third-generation cephalosporin antibiotic. It has broad-spectrum activity against Gram-positive and ... In patients with renal impairment a dose reduction may be needed.[citation needed] Cefotiam has a broad spectrum of activity ... Kolben M, Mandoki E, Ulm K, Freitag K (January 2001). "Randomized trial of cefotiam prophylaxis in the prevention of ... Müller R, Böttger C, Wichmann G (2003). "Suitability of cefotiam and cefuroxime axetil for the perioperative short-term ...
... is a second-generation cephalosporin antibiotic.[citation needed] Cefotiam Crowle A, Sbarbaro J, May M (1988). " ...
The aminothiazole ring can be seen in the structure of cefotiam. The majority of third generation cephalosporins have the ...
... cefotiam (INN) cefovecin sodium (USAN) cefoxazole (INN) cefoxitin (INN) cefozopran (INN) cefpimizole (INN) cefpiramide (INN) ...
... cefotiam MeSH D02.065.589.099.249.190.190.145 - ceftizoxime MeSH D02.065.589.099.249.190.190.155 - ceftriaxone MeSH D02.065. ...
J01DC01 Cefoxitin J01DC02 Cefuroxime J01DC03 Cefamandole J01DC04 Cefaclor J01DC05 Cefotetan J01DC06 Cefonicide J01DC07 Cefotiam ...
... cefotiam 1981 - cefsulodin 1981 - latamoxef 1981 - netilmicin 1982 - ceftriaxone 1982 - micronomicin 1983 - cefmenoxime 1983 - ...
Cefotiam is a parenteral third-generation cephalosporin antibiotic. It has broad-spectrum activity against Gram-positive and ... In patients with renal impairment a dose reduction may be needed.[citation needed] Cefotiam has a broad spectrum of activity ... Kolben M, Mandoki E, Ulm K, Freitag K (January 2001). "Randomized trial of cefotiam prophylaxis in the prevention of ... Müller R, Böttger C, Wichmann G (2003). "Suitability of cefotiam and cefuroxime axetil for the perioperative short-term ...
Get up-to-date information on Cefotiam side effects, uses, dosage, overdose, pregnancy, alcohol and more. Learn more about ... How was your experience with Cefotiam?. First, a little about yourself. Male Female ...
Cefotiam ‐ A cephalosporin antibiotic that has a broad spectrum of activity… ...
cefotiam. 1981 cefsulodin. 1981 latamoxef. 1981 netilmicin. 1982 ceftriaxone. 1982 micronomicin. 1983 cefmenoxime. 1983 ...
As we supply a wide variety of ingredients to serve pharmaceutical (human and vet.), cosmetics, and food sectors.. We Are a Global Sourcing Agent that has Partnerships in China, India, and Pakistan so you can consider us as your sourcing partner.. We work in stocking pharmaceuticals in our warehouse or serving our clients with a suitable factory wherever it is, ensuring high-quality products.. Helping our Egyptian clients to Register their products in EDA to enable them to import by themselves through us as an agent for foreign factories.. So, simply wherever you are, we are there.. ...
Cefotiam Susc Islt 3 LOINC_Long_Common_Name LOINC Long Common Name Cefotiam [Susceptibility] ...
Cefotiam D2.886.675.966.500.249.190.190.135 D2.886.665.74.190.190.135. D4.75.80.875.99.221.249.190.190.135. Cefoxitin D2.886. ...
Cefotiam D2.886.675.966.500.249.190.190.135 D2.886.665.74.190.190.135. D4.75.80.875.99.221.249.190.190.135. Cefoxitin D2.886. ...
Im Allergologie-Index finden Sie alle Index-Einträge alphabetisch sortiert.
In total, 1348 patients were included in our study, all of whom received antibiotic prophylaxis (cefotiam or cefuroxime) during ...
... cefotiam hexetil hydrochloride, cefpodoxime proxetil, cefuroxime axetil, dapsone, dexamethasone, doxycycline, famotidine, ...
Cefotiam [D02.065.589.099.249.190.190.135] * Ceftizoxime [D02.065.589.099.249.190.190.145] * Ceftriaxone [D02.065.589.099. ...
InChI=1S/C66H75Cl2N9O24/c1-23(2)12-34(71-5)58(88)76-49-51(83)26-7-10-38(32(67)14-26)97-40-16-28-17-41(55(40)101-65-56(54(86)53(85)42(22-78)99-65)100-44-21-66(4,70)57(87)24(3)96-44)98-39-11-8-27(15-33(39)68)52(84)50-63(93)75-48(64(94)95)31-18-29(79)19-37(81)45(31)30-13-25(6-9-36(30)80)46(60(90)77-50)74-61(91)47(28)73-59(89)35(20-43(69)82)72-62(49)92/h6-11,13-19,23-24,34-35,42,44,46-54,56-57,65,71,78-81,83-87H,12,20-22,70H2,1-5H3,(H2,69,82)(H,72,92)(H,73,89)(H,74,91)(H,75,93)(H,76,88)(H,77,90)(H,94,95)/t24-,34+,35-,42+,44-,46+,47+,48-,49+,50-,51+,52+,53+,54-,56+,57+,65-,66-/m0/s1 ...
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.. ...
Cyclobenzaprine is also known as Synonym. SynZeal provides high-quality Cyclobenzaprine Reference Standard, pharmacopeial and non-pharmacopeial impurities, degradants, and stable isotope products.
J01DC07: cefotiam - cefotiam *J01DC08: loracarbef - loracarbef *J01DC09: cefmetazol - cefmetazole *J01DC10: cefprozilo - ...
Cefotiam. Furosemide. Methotrexate. Olmesartan. Pravastatin. [138,139,142,143,149,229-238]. Oct2. Brain. Lung. Renal proximal ...
Cefotiam / therapeutic use* Actions. * Search in PubMed * Search in MeSH * Add to Search ...
Cefotiam D2.886.675.966.500.249.190.190.135 D2.886.665.74.190.190.135. D4.75.80.875.99.221.249.190.190.135. Cefoxitin D2.886. ...
Cefotiam ‐ A cephalosporin antibiotic that has a broad spectrum of activity… ...
Biodegradability of cefotiam, ciprofloxacin, meropenem, penicillin G, and sulfamethoxazole and inhibition of waste water ...
Cefotiam_Hydrochloride,modify,30-APR-07,(null),(null) C2687,Visilizumab,modify,30-APR-07,(null),(null) C62051,Morphine_Base, ... Cefotiam,modify,30-APR-07,(null),(null) C66323,Pargyline_Hydrochloride,modify,30-APR-07,(null),(null) C28863,Benzonatate,modify ...
Cefotiam (substance). Code System Preferred Concept Name. Cefotiam (substance). Concept Status. Published. ...
Cefotiam Hydrochloride Narrower Concept UI. M0351050. Registry Number. H7V12WDZ93. Terms. Cefotiam Hydrochloride Preferred Term ... Cefotiam Preferred Concept UI. M0023572. Registry Number. 91W6Z2N718. Related Numbers. 61622-34-2. H7V12WDZ93. Scope Note. One ... Cefotiam Preferred Term Term UI T045018. Date01/01/1999. LexicalTag NON. ThesaurusID ... Cefotiam Hydrochloride Ceradolan Haloapor Halospor SCE-963 Pharm Action. Anti-Bacterial Agents. Registry Number. 91W6Z2N718. ...
Cefotiam Hydrochloride Narrower Concept UI. M0351050. Registry Number. H7V12WDZ93. Terms. Cefotiam Hydrochloride Preferred Term ... Cefotiam Preferred Concept UI. M0023572. Registry Number. 91W6Z2N718. Related Numbers. 61622-34-2. H7V12WDZ93. Scope Note. One ... Cefotiam Preferred Term Term UI T045018. Date01/01/1999. LexicalTag NON. ThesaurusID ... Cefotiam Hydrochloride Ceradolan Haloapor Halospor SCE-963 Pharm Action. Anti-Bacterial Agents. Registry Number. 91W6Z2N718. ...
Cefotiam, cyclophosphamide. Discharged. 4. 71/F. Uremia, nephrotic syndrome. Gross hematuria, edema. 250 mg/day for 3 days + ...
Its main uses are in intensive care medicine (pneumonia, peritonitis), some diabetes-related foot infections, and empirical therapy in febrile neutropenia (e.g., after chemotherapy). The drug is administered intravenously every 6 or 8 hr, typically over 3-30 min. It may also be administered by continuous infusion over four hours. Prolonged infusions are thought to maximize the time that serum concentrations are above the minimum inhibitory concentration (MIC) of the bacteria implicated in infection.[citation needed] Piperacillin-tazobactam is recommended by the National Institute for Health and Care Excellence as first-line therapy for the treatment of bloodstream infections in neutropenic cancer patients.[7] For β-lactam antipseudomonal antibiotics, including piperacillin/tazobactam, prolonged intravenous infusion is associated with lower mortality than bolus intravenous infusion in persons with sepsis due to Pseudomonas aeruginosa.[8] ...
... cause cefotiam,cefotiam center,center cetacido,cetacido cetoacil,cetoacil cetoprostaglandina,cetoprostaglandina ...
세포티암(cefotiam). 세푸록심(cefuroxime) 세포탁심(cefotaxime). 세프트리악손(ceftriaxone) 세프타지딤(ceftazidime) 세페핌(cefepime) ...
As we supply a wide variety of ingredients to serve pharmaceutical (human and vet.), cosmetics, and food sectors.. We Are a Global Sourcing Agent that has Partnerships in China, India, and Pakistan so you can consider us as your sourcing partner.. We work in stocking pharmaceuticals in our warehouse or serving our clients with a suitable factory wherever it is, ensuring high-quality products.. Helping our Egyptian clients to Register their products in EDA to enable them to import by themselves through us as an agent for foreign factories.. So, simply wherever you are, we are there.. ...
Some antibiotics, including cefuroxime and cefotiam [66]. *Antimalarials, such as chloroquine [66] ...
... cefotiam hydrochloride, E0300848,Cerespan,papaverine hydrochloride, E0300882,Chlorocid,chloramphenicol, E0300883,Detreomycin, ...
Generic since isouretin, another collacin Amoy nonseasonably follow that of myself cefotiam. *Nephological ...
Cefotiam D2.886.675.966.500.249.190.190.135 D2.886.665.74.190.190.135. D4.75.80.875.99.221.249.190.190.135. Cefoxitin D2.886. ...
RESULTS: The median length of hospital stay was 6, 5, and 5 days in the cefotiam, fosfomycin, and other antibacterial groups, ... There were no significant differences in the median age or surgery time between the cefotiam and fosfomycin groups. Propensity ... CONCLUSIONS: During a period of difficulty in acquiring cefazolin and cefotiam, the use of fosfomycin allowed us to continue ... In addition, there was a difficulty in supplying drugs alternative to cefazolin, such as cefotiam and cefmetazole. In our ...
D4.75.80.875.99.221.249.250.199 Cefotiam D2.886.675.966.500.249.190.190.135 D2.886.665.74.190.190.135 D4.75.80.875.99.221. ...
... cause cefotiam,cefotiam center,center cetacido,cetacido cetoacil,cetoacil cetoprostaglandina,cetoprostaglandina ...
Camylofin is also known as Synonym. SynZeal provides high-quality Camylofin Reference Standard, pharmacopeial and non-pharmacopeial impurities, degradants, and stable isotope products.
Cefpodoxime, sold under the brand name Vantin among others, is an antibiotic used to treat middle ear infections, strep throat, sinusitis, urinary tract infections, and gonorrhea.[2] It is taken by mouth.[2] Common side effects include diarrhea, nausea, vaginal yeast infections, abdominal pain, and headache.[3] Other side effects may include allergic reactions and Clostridioides difficile infection.[2] While there is no evidence of harm with use in pregnancy, such use has not been well studied.[4] It is a third-generation cephalosporin and works by interfering with the bacterial cell wall.[1] Cefpodoxime was patented in 1980 and approved for medical use in 1989.[5] It is available as a generic medication.[2] In the United States 20 tablets of 200 mg costs about 36 USD as of 2021.[6] ...
  • Cefotiam is a parenteral third-generation cephalosporin antibiotic. (wikipedia.org)
  • In total, 1348 patients were included in our study, all of whom received antibiotic prophylaxis (cefotiam or cefuroxime) during the first debridement at the emergency room. (bvsalud.org)
  • citation needed] Cefotiam has a broad spectrum of activity and has been used to treat infections caused by a number of enteric bacteria and bacteria responsible for causing skin infections. (wikipedia.org)